FDA Approves Leucovorin for Rare Disorder Despite Limited Trial Data

The FDA's approval of leucovorin for a rare disorder highlights gaps in clinical trial data but underscores urgency in addressing unmet medical needs. Biotech investor Alexis Borisy's support of Boris Nikolic's comeback reveals interconnected influences in biotech funding. Going forward, increased scrutiny on approval processes and insider support in biotech will be key areas to monitor.